BMS-790052
- Catalog NO.:A897299
- CAS No. : 1009119-64-5
- Molecular Formula:C40H50N8O6
- Molecular Weight: 738.88
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Quality Control&SDS
Product Details
CAS Number | 1009119-64-5 | Appearance | |
Catalog Number | A897299 | MDL Number | MFCD17129086 |
Molecular Formula | C40H50N8O6 | Molecular Weight | 738.88 |
Boiling Point | 1071.2±65.0°C at 760 mmHg | Melting Point | |
Flash Point | Density | ||
Synonyms | Daclatasvir;BMS 790052; EBP 883; methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate;Daclatasvir | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H319-H335 | Class | |
Precautionary Statements | P261-P305+P351+P338 | Packing Group |
Description
Daclatasvir (USAN), also known as BMS-790052 and EBP-883 (trade name Daklinza), is NS5A inhibitor and a drug for the treatment of hepatitis C (HCV). It is was developed by Bristol-Myers Squibb and was approved in Europe on 22 August 2014. Daclatasvir inhibits the HCV nonstructural protein NS5A. Recent research suggests that it targets two steps of the viral replication process, enabling rapid decline of HCV RNA. Daclatasvir has been tested in combination regimens with pegylated interferon and ribavirin, as well as with other direct-acting antiviral agents including asunaprevir and sofosbuvir. |